CoChat
Sign Up
Cited by 13Gastrointestinal motility and disordersAutoimmune Neurological Disorders and TreatmentsPeripheral Neuropathies and Disorders

Neural autoantibody evaluation in functional gastrointestinal disorders: a population-based case-control study

Open access
Pittock, Sean J., Lennon, Vanda A., Dege, Carissa L., Talley, Nicholas J., Locke, G. Richard·2011·Digestive Diseases and Sciences
DOI 10.1007/s10620-010-1514-9PMC PMC3089890
Open this paper in CoChat — free account

Abstract

Background Our goal is to investigate the serum profile of neural autoantibodies in community-based patients with irritable bowel syndrome (IBS) or functional dyspepsia. The pathogenesis of functional gastrointestinal (GI) disorders, including IBS and dyspepsia, are unknown. Theories range from purely psychological to autoimmune alterations in GI tract neuromuscular function. Methods The study subjects, based in Olmsted County, MN, reported symptoms of functional dyspepsia or IBS (n = 69), or were asymptomatic controls (n = 64). Their coded sera were screened for antibodies targeting neuronal, glial, and muscle autoantigens. Results The prevalence of neural autoantibodies with functional GI disorders did not differ significantly from controls (17% vs. 13%; P = 0.43). In no case was a neuronal or glial nuclear autoantibody or enteric neuronal autoantibody identified. Neuronal cation channel antibodies were identified in 9% of cases (voltage-gated potassium channel [VGKC] in one dyspepsia case and one IBS case, ganglionic acetylcholine receptor [AChR] in four IBS cases) and in 6% of controls (ganglionic AChR in one, voltage-gated calcium channel [VGCC], N-type, in two and VGKC in one; P = 0.36). The frequency of glutamic acid decarboxylase-65 (GAD65) autoantibodies was similar in cases (10%) and controls (5%; P = 0.23). Conclusions Our data do not support neural autoimmunity as the basis for most IBS or functional dyspepsia cases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s10620-010-1514-9

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Autoantibodies directed against specific neural antigens, including ion channels and ganglionic acetylcholine receptors, have been associated with esophageal dysmotility, slow-transit constipation, and chronic intestinal pseudo-obstruction.

    “Autoantibodies directed against specific neural antigens (including ion channels and ganglionic acetylcholine receptors) have been associated with esophageal dysmotility, slow-transit constipation, and chronic intestinal pseudo-obstruction.”

    From Autonomic nervous system and gastrointestinal manifestations with an emphasis on gastric dysfunction (2026) · cites this paper as Pittock et al., 2011

    The Introduction links ganglionic acetylcholine receptor antibodies to autoimmune gastrointestinal dysmotility, describes pseudo-obstruction as a prominent presentation, and reports slow GI transit in animal models. It also reports an association between a different neural antibody and achalasia. The paper does not establish the claimed association of ion-channel and ganglionic receptor antibodies with all three named conditions, particularly slow-transit constipation; its own cases and controls did not develop GI dysmotility during follow-up (Results). (LLM, conf=0.82)

    Experimental — accuracy not yet measured

  • In cohorts of patients with idiopathic, paraneoplastic, or diabetic autonomic neuropathy and in idiopathic GI dysmotility, ganglionic receptor-binding antibody titers have correlated with more severe autonomic dysfunction.

    “In cohorts of patients with idiopathic, paraneoplastic, or diabetic autonomic neuropathy and in idiopathic GI dysmotility, ganglionic receptor-binding antibody titers have correlated with more severe autonomic dysfunction (Dhamija et al., 2008; Pittock et al., 2011).”

    From Autonomic nervous system and gastrointestinal manifestations with an emphasis on gastric dysfunction (2026) · cites this paper as Pittock et al., 2011

    The Discussion (page unavailable) reports that higher ganglionic AChR antibody levels were more often accompanied by clinical evidence of an autoimmune neurological disorder, and it mentions idiopathic and paraneoplastic dysautonomia. It does not report a correlation between antibody titer and the severity of autonomic dysfunction in the listed cohorts, including diabetic neuropathy or idiopathic GI dysmotility. In this study, seropositive cases had low levels and developed no dysautonomia during follow-up. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The citation lists haven’t been fetched yet

References 45 · Cited by 13

Research works printed but not linked: 35

  1. [4]Smith VV Gregson N Foggensteiner L Neale G Milla PJ Acquired intestinal aganglionosis and circulating autoantibodies without neoplasia or other neural involvement Gastroenterology 1997 112 1366 1371 9098023
  2. [6]Lennon VA Ermilov LG Szurszewski JH Vernino S Immunization with neuronal nicotinic acetylcholine receptor induces neurological autoimmune disease J Clin Invest 2003 111 907 913 12639997 PMC153771
  3. [7]Kraichely RE Farrugia G Pittock SJ Castell DO Lennon VA Neural autoantibody profile of primary achalasia Dig Dis Sci 2010 55 307 311 19499338 PMC2819289
  4. [9]Talley NJ Stanghellini V Heading RC Koch KL Malagelada JR Tytgat GN Functional gastroduodenal disorders Gut 1999 45 II37 II42 10457043 PMC1766695
  5. [10]Spiller R Aziz Q Creed F Emmanuel A Houghton L Hungin P Jones R Kumar D Rubin G Trudgill N Whorwell P Clinical Services Committee of The British Society of Gastroenterology Guidelines on the irritable bowel syndrome: mechanisms and practical management Gut 2007 56 1770 1798 17488783 PMC2095723
  6. [11]Talley NJ Irritable bowel syndrome Intern Med J 2006 36 724 728 17040359 PMC1761148
  7. [13]Grundmann O Yoon SL Irritable bowel syndrome: epidemiology, diagnosis and treatment: an update for health-care practitioners J Gastroenterol Hepatol 2010 25 691 699 20074154
  8. [15]Cash BD Schoenfeld P Chey WD The utility of diagnostic tests in irritable bowel syndrome patients: a systematic review Am J Gastroenterol 2002 97 2812 2819 12425553
  9. [16]Törnblom H Lang B Clover L Knowles CH Vincent A Lindberg G Autoantibodies in patients with gut motility disorders and enteric neuropathy Scand J Gastroenterol 2007 42 1289 1293 17918010
  10. [17]Collins SM Piche T Rampal P The putative role of inflammation in the irritable bowel syndrome Gut 2001 49 743 745 11709500 PMC1728553
  11. [18]Bercik P Verdu EF Collins SM Is irritable bowel syndrome a low-grade inflammatory bowel disease? Gastroenterol Clin North Am 2005 34 235 245 15862932
  12. [19]Mayer EA Inflammation in irritable bowel syndrome: curiosity or culprit J Pediatr Gastroenterol Nutr 2004 39 S751 S753 15167375
  13. [20]Tan KM Lennon VA Klein CJ Boeve BF Pittock SJ Clinical spectrum of voltage-gated potassium channel autoimmunity Neurology 2008 70 1883 1890 18474843
  14. [21]Locke GR 3rd Murray JA Zinsmeister AR Melton LJ 3rd Talley NJ Celiac disease serology in irritable bowel syndrome and dyspepsia: a population-based case–control study Mayo Clin Proc 2004 79 476 482 15065612
  15. [22]Locke CR 3rd Talley NJ Nelson DK Haruma K Weaver AL Zinsmeister AR Melton LJ 3rd Helicobacter pylori and dyspepsia: a population-based study of the organism and host Am J Gastroenterol 2000 95 1906 1913 10950034
  16. [23]Talley NJ Zinsmeister AR Schleck CD Melton LJ 3rd Smoking, alcohol, and analgesics in dyspepsia and among dyspepsia subgroups: lack of an association in a community Gut 1994 35 619 624 8200553 PMC1374744
  17. [24]Talley NJ Phillips SF Melton J 3rd Wiltgen C Zinsmeister AR A patient questionnaire to identify bowel disease Ann Intern Med 1989 111 671 674 2679285
  18. [25]Manning AP Thompson WG Heaton KW Morris AF Towards positive diagnosis of the irritable bowel Br Med J 1978 2 653 654 698649 PMC1607467
  19. [26]Lennon VA The case for a descriptive generic nomenclature: clarification of immunostaining criteria for PCA-1, ANNA-1, and ANNA-2 autoantibodies Neurology 1994 44 2412 2415 7991144
  20. [27]Yu Z Kryzer TJ Griesmann GE Kim K Benarroch EE Lennon VA CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity Ann Neurol 2001 49 146 154 11220734
  21. [28]Vernino S Lennon VA New Purkinje cell antibody (PCA-2): marker of lung cancer-related neurological autoimmunity Ann Neurol 2000 47 297 305 10716248
  22. [29]Chamberlain JL Pittock SJ Oprescu AM Dege C Apiwattanakul M Kryzer TJ Lennon VA Peripherin-IgG association with neurologic and endocrine autoimmunity J Autoimmun 2010 34 469 477 20061119 PMC2902873
  23. [30]Lennon VA Kryzer TJ Griesmann GE O’Suilleabhain PE Windebank AJ Woppmann A Miljanich GP Lambert EH Calcium-channel antibodies in the Lambert–Eaton syndrome and other paraneoplastic syndromes N Engl J Med 1995 332 1467 1474 7739683
  24. [31]Griesmann GE Kryzer TJ Lennon VA Rose NR Hamilton RG Detrick B Autoantibody profiles of myasthenia gravis and Lambert–Eaton myasthenic syndrome Manual of clinical and laboratory immunology 2002 1005 1012 ASM Press Washington, DC
  25. [32]Vernino S Kryzer TJ Lennon VA Rose NR Hamilton RG Detrick B Autoimmune autonomic neuropathy and neuromuscular hyperexcitability disorders Manual of clinical and laboratory immunology 2002 1013 1017 ASM Press Washington, DC
  26. [33]Pittock SJ Yoshikawa H Ahlskog JE Tisch SH Benarroch EE Kryzer TJ Lennon VA Glutamic acid decarboxylase autoimmunity with brainstem, extrapyramidal, and spinal cord dysfunction Mayo Clin Proc 2006 81 1207 1214 16970217
  27. [34]Cikes N Momoi MY Williams CL Howard FM Jr Hoagland HC Whittingham S Lennon VA Striational autoantibodies: quantitative detection by enzyme immunoassay in myasthenia gravis, thymoma, and recipients of d-penicillamine or allogeneic bone marrow Mayo Clin Proc 1988 63 474 481 3283472
  28. [35]Keegan BM Pittock SJ Lennon VA Autoimmune myelopathy associated with collapsin response-mediator protein-5 immunoglobulin G Ann Neurol 2008 63 531 534 18306241
  29. [36]Clarke G Quigley EM Cryan JF Dinan TG Irritable bowel syndrome: towards biomarker identification Trends Mol Med 2009 15 478 489 19811951
  30. [37]Walikonis JE Lennon VA Radioimmunoassay for glutamic acid decarboxylase (GAD65) autoantibodies as a diagnostic aid for stiff-man syndrome and a correlate of susceptibility to type 1 diabetes mellitus Mayo Clin Proc 1998 73 1161 1166 9868413
  31. [39]Klein CM Vernino S Lennon VA Sandroni P Fealey RD Benrud-Larson L Sletten D Low PA The spectrum of autoimmune autonomic neuropathies Ann Neurol 2003 53 752 758 12783421
  32. [40]Pasha SF Lunsford TN Lennon VA Autoimmune gastrointestinal dysmotility treated successfully with pyridostigmine Gastroenterology 2006 131 1592 1596 17101331
  33. [41]Lee HR Lennon VA Camilleri M Prather CM Paraneoplastic gastrointestinal motor dysfunction: clinical and laboratory characteristics Am J Gastroenterol 2001 96 373 379 11232678
  34. [42]Lennon VA Peter JB Schoenfeld Y Calcium channel and related paraneoplastic disease autoantibodies Textbook of autoantibodies 1996 139 147 Elsevier Science Publishers, B.V. Amsterdam
  35. [43]Törnblom H Lindberg G Nyberg B Veress B Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome Gastroenterology 2002 123 1972 1979 12454854

Authors
Pittock, S. J., Lennon, V. A., Dege, C. L., Talley, N. J., & Locke, G. R.
Affiliations
Mayo Clinic (US)
Corresponding author
  • Pittock, Sean J.
  • Locke, G. Richard
ORCID
Venue
Digestive Diseases and Sciences
Publisher
Springer Science and Business Media LLC
Published
2010-12-23
Volume
56
Issue
5
Pages
1452-1459
ISSN
  • 0163-2116 (ISSN-L)
  • 1573-2568
DOI
10.1007/s10620-010-1514-9
PMC
PMC3089890
OpenAlex
W2079105897
Cited by
13
References
45
Citations by year
2026: 1 · 2024: 1 · 2021: 2 · 2020: 1 · 2018: 2 · 2015: 1 · 2014: 2 · 2013: 1 · 2012: 2
FWCI
0.99
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Digestive Diseases and Sciences (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • American College of Gastroenterology
  • National Institutes of Health
  • National Institute on Aging (R01AG034676)
  • National Institute of Diabetes and Digestive and Kidney Diseases (DK 71209, R01DK057892, DK-68055, R01DK071209, P01DK068055)
  • National Institute of Arthritis and Musculoskeletal and Skin Diseases (R01AR030582, AR30582)
  • National Center for Research Resources (M01 RR585, M01RR000585)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Neurology › Autoimmune Neurological Disorders and Treatments
  • Health Sciences › Medicine › Neurology › Peripheral Neuropathies and Disorders
Keywords
neural autoantibodies, irritable bowel syndrome, functional dyspepsia, functional gastrointestinal disorders, autoimmunity, voltage-gated potassium channel antibodies, enteric neurons
MeSH terms
Adult, Autoantibodies, Dyspepsia, Female, Humans, Male, Neuroglia, Neurons, Case-Control Studies, Muscle, Skeletal, Irritable Bowel Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review